Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine

BACKGROUND: Lamivudine inhibits replication of both human immunodeficiency virus (HIV) and hepatitis B virus (HBV) and is commonly used as part of antiretroviral therapy. The main limitation in the use of lamivudine is resistant mutation selection. Most of these mutations affect the YMDD motif of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Eneida A, Sucupira, Michel VF, Arabe, Juçara, Gomes, Selma A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC516776/
https://www.ncbi.nlm.nih.gov/pubmed/15339340
http://dx.doi.org/10.1186/1471-2334-4-29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC516776/
https://www.ncbi.nlm.nih.gov/pubmed/15339340
http://dx.doi.org/10.1186/1471-2334-4-29

Ejemplares similares